Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

In May, Lexicon announced its results of LX4211, an SGLT-1/SGLT-2 inhibitor. The phase 2 trial finished its open-label, pioneer section, which showed a decrease in...
On April 29, Merck and Pfizer announced that they are entering a partnership to develop ertugliflozin for type 2 diabetes. Ertugliflozin is a sodium-glucose linked...
On June 5 and 6, an FDA advisory panel voted in favor of modifying the current Risk Evaluation and Modification Strategy (REMS), for GlaxoSmithKline’s (GSK) Avandia (...
The consensus from most speakers at the workshop was that, while this possible link does require further investigation, the available evidence does not suggest any need...
What it felt like to forget about diabetes for a week.
On April 16, Vivus announced that the FDA approved a change to the distribution of Qsymia . Qsymia is a weight loss and weight management drug that is designed to be...
On March 25, Lilly and Boehringer Ingelheim (BI) announced that they submitted an application to the FDA for empagliflozin, an SGLT-2 inhibitor, for type 2 diabetes...
The Food and Drug Administration (FDA) on March 29, 2013 announced its approval of Janssen Pharmaceuticals' Invokana (canagliflozin), a new SGLT-2 inhibitor for type 2...
On March 1, Vivus started its Save Now! program, which sets a discounted price of $75 for one 30-day supply of the company’s weight management medication Qsymia (7.5 mg...
In March 2013, Novo Nordisk launched Tresiba (insulin degludec) , its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be...
A study in the Journal of the American Medical Association ( JAMA ) found that patients with type 2 diabetes who had been taking the GLP-1 agonists Bydureon (exenatide...
On February 1, the European Commission announced that it had approved Sanofi and Zealand Pharma’s GLP-1 agonist Lyxumia (lixisenatide) for type 2 diabetes. The drug is a...
In January, the FDA announced the approval of three of Takeda’s new once-daily DPP-4 inhibitor pills for type 2 diabetes. DPP-4 inhibitors have been the best-selling...
On February 8, Novo Nordisk received an FDA complete response letter (CRL) for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/aspart). Tresiba is Novo Nordisk’...
How can the FDA change its view on drug approvals to give patients access to better therapies?
Can a drug for type 2 diabetes work for those with type 1? How will a new basal insulin compare to Lantus?
What’s an SGLT-2 inhibitor and how does it work? Includes cool FAQ!
Dr. Sanjay Kaul speaks to diaTribe about the new SGLT-2 drug class.
On January 11, an advisory panel recommended that the FDA approve Johnson & Johnson’s SGLT-2 inhibitor, Invokana (canagliflozin). The panel voted 10-5 in favor of...
Kelly on a heated day at the FDA and why a new drug class could bring diabetes patients, doctors, and educators closer to personalized therapy.

Pages